Modest Nonadherence to Antiretroviral Therapy Promotes Residual HIV-1 Replication in the Absence of Virological Rebound in Plasma

Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy

(2011) Alex Sigal et al.   NATURE

Episomal Viral cDNAs Identify a Reservoir That Fuels Viral Rebound after Treatment Interruption and That Contributes to Treatment Failure

(2011) Mark Sharkey et al.   PLoS Pathogens

Steady increase in cellular HIV-1 load during the asymptomatic phase of untreated infection despite stable plasma viremia

(2010) Alexander O Pasternak et al.   AIDS

Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy

(2010) Steven A Yukl et al.   AIDS

HIV Infection, Inflammation, Immunosenescence, and Aging

(2010) Steven G. Deeks   Annual Review of Medicine

Average Adherence to Boosted Protease Inhibitor Therapy, rather than the Pattern of Missed Doses, as a Predictor of HIV RNA Replication

(2010) Jean‐Jacques Parienti et al.   CLINICAL INFECTIOUS DISEASES

Electronic monitoring-based counseling to enhance adherence among HIV-infected patients: A randomized controlled trial.

(2010) Marijn de Bruin et al.   HEALTH PSYCHOLOGY

Risk of Viral Failure Declines With Duration of Suppression on Highly Active Antiretroviral Therapy Irrespective of Adherence Level

(2010) Viviane D Lima et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Differences in HIV Burden and Immune Activation within the Gut of HIV‐Positive Patients Receiving Suppressive Antiretroviral Therapy

(2010) Steven A. Yukl et al.   JOURNAL OF INFECTIOUS DISEASES

HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects

(2010) Maria J Buzón et al.   NATURE MEDICINE

Profound Depletion of HIV-1 Transcription in Patients Initiating Antiretroviral Therapy during Acute Infection

(2010) Adrian Schmid et al.   PLoS One

Targeting viral reservoirs: ability of antiretroviral therapy to stop viral replication

(2010) Frank Maldarelli   Current Opinion in HIV and AIDS

The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial

(2010) Rajesh T. Gandhi et al.   PLOS MEDICINE

Immune activation and AIDS pathogenesis

(2009) Donald L Sodora et al.   AIDS

Antiretroviral medication adherence and the development of class-specific antiretroviral resistance

(2009) Edward M Gardner et al.   AIDS

The Risk of Virologic Failure Decreases with Duration of HIV Suppression, at Greater than 50% Adherence to Antiretroviral Therapy

(2009) Michael Rosenblum et al.   PLoS One

Cellular Levels of HIV Unspliced RNA from Patients on Combination Antiretroviral Therapy with Undetectable Plasma Viremia Predict the Therapy Outcome

(2009) Alexander O. Pasternak et al.   PLoS One

The Relationship Between Resistance and Adherence in Drug-Naive Individuals Initiating HAART Is Specific to Individual Drug Classes

(2008) Lily W Y Tam et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection

(2008) Lin Shen et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Forgiveness of non-adherence to HIV-1 antiretroviral therapy

(2008) J. Shuter   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Highly Sensitive Methods Based on Seminested Real-Time Reverse Transcription-PCR for Quantitation of Human Immunodeficiency Virus Type 1 Unspliced and Multiply Spliced RNA and Proviral DNA

(2008) A. O. Pasternak et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Preventing HIV Antiretroviral Resistance through Better Monitoring of Treatment Adherence

(2008) David R. Bangsberg   JOURNAL OF INFECTIOUS DISEASES

Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies

(2008)   LANCET

Not All Missed Doses Are the Same: Sustained NNRTI Treatment Interruptions Predict HIV Rebound at Low-to-Moderate Adherence Levels

(2008) Jean-Jacques Parienti et al.   PLoS One

Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy

(2008) S. Palmer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

HIV rebounds from latently infected cells, rather than from continuing low-level replication

(2008) B. Joos et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Biphasic decay kinetics suggest progressive slowing in turnover of latently HIV-1 infected cells during antiretroviral therapy

(2008) Marek Fischer et al.   Retrovirology